“We appreciate the attention that ICER’s review has brought to a disease that is often overlooked and undertreated. These new CGRP inhibitors are the first medicines developed and approved for the prevention of migraine attacks. With ICER finding that these medicines are cost-effective for migraine patients that have been failed by other treatments, we call on all stakeholders in healthcare to work together to ensure that the millions of Americans who endure the pain and disabling effects of migraine disease have full and unrestricted access to these life-changing medicines.”

-Kevin Lenaburg

Executive Director, CHAMP

To read the full ICER Migraine Evidence Report released May 31, 2018, click here.

 

Posted in